Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort | AIDS Research and Therapy | Full Text

Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort | AIDS Research and Therapy | Full Text

Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

Dolutegravir (DTG)-based antiretroviral therapy (ART) is currently the first-line treatment for people living with HIV. Neuropsychiatric adverse events (NP-AEs) have been reported with DTG but neuropsychiatric...

Authors:Phillip Chan, Orlanda Goh, Eugène Kroon, Donn Colby, Carlo Sacdalan, Suteeraporn Pinyakorn, Peeriya Prueksakaew, Peter Reiss, Jintanat Ananworanich, Victor Valcour, Serena Spudich and Robert Paul

Citation:AIDS Research and Therapy 2020 17:1

Content type:Research

Published on: 7 January 2020

• ViewFull Text
 
• ViewPDF